Investment Rating - The investment rating for the company is "Outperform the Market" [6][3] Core Viewpoints - The company reported a revenue of 469 million yuan in 2024, a decrease of 3.13%, with a net profit of 141 million yuan, down 4.08%. However, Q4 2024 showed a strong performance with a revenue of 106 million yuan, an increase of 29.77%, and a net profit of 42 million yuan, up 733.85% [1][9] - The company is focusing on expanding its ultrasound matrix and the application of SonoAI technology to enhance product competitiveness [1][9] - The gross margin for 2024 was stable at 58.95%, while the R&D expense ratio increased to 16.99%, reflecting the company's commitment to building technological barriers through increased R&D investment [2][15] - The company is deeply engaged in the ultrasound AI field, driving innovation across various clinical disciplines with products like the "Breast AI Ultrasound Robot" [2][20] Financial Forecasts - The revenue forecasts for 2025, 2026, and 2027 are adjusted to 560 million yuan, 640 million yuan, and 740 million yuan respectively, with year-on-year growth rates of 19%, 15%, and 14% [3][20] - The net profit forecasts for the same period are 170 million yuan, 200 million yuan, and 220 million yuan, with growth rates of 21%, 15%, and 15% [3][20] - The current stock price corresponds to a PE ratio of 19, 17, and 15 for 2025, 2026, and 2027 respectively [3][20]

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical industry faced revenue pressure in Q1 2025, with varied performance across segments. Biologics grew by 12% driven by overseas business, hospitals increased by 6.7%, and medical consumables rose by 1.8% [1][3][4]. Core Insights and Arguments - **CXO and IVD Focus**: Public fund holdings indicate that CXO (Contract Research Organization) and IVD (In Vitro Diagnostics) are key market focuses. Companies like WuXi AppTec and Kelun are benefiting from overseas business, with high capacity utilization [1][4]. - **CXO Characteristics**: The CXO sector in Q1 2025 showed strong overseas-driven growth, with improved domestic new orders but overall performance lagging behind international results. Leading companies exhibit strong stability, while smaller firms are relatively weaker [5][6]. - **IVD Sector Decline**: The IVD industry experienced negative growth in Q1 2025, with reagent consumption declining year-on-year. The chemiluminescence sector performed better due to import substitution, while companies like Mindray faced challenges from mature business impacts [1][9]. - **Policy Impact on IVD**: Domestic policies such as DRG 2.0 and medical service price adjustments significantly affected the IVD sector, leading to decreased testing prices and reduced profitability for channels, impacting overall testing volumes [10]. Additional Important Insights - **Medical Equipment Recovery**: The medical equipment sector showed signs of recovery, with a more than 60% year-on-year increase in procurement in Q1 2025, particularly in tertiary hospitals. Expectations for better performance in the second half of the year are optimistic [1][16]. - **Investment Opportunities**: Areas with potential for high growth include innovative drugs, CXO, biologics, and hospital services, driven by new product launches and increased international market demand [7][21]. - **Market Trends**: The medical device sector is expected to improve in the second half of 2025, with procurement demand recovering after a significant decline in 2024 [14][16]. - **International Market Influence**: Chinese medical device companies are seeing significant contributions from international markets, with notable growth rates in overseas business for companies like Mindray and United Imaging [17]. Fund Holdings and Market Sentiment - **Biopharmaceutical Fund Allocation**: In Q1 2025, biopharmaceuticals accounted for 9.2% of the top ten fund holdings, indicating a positive sentiment towards the sector despite a historical trend of under-allocation since 2021 [18][19]. - **Hospital Sector Holdings**: The hospital sector saw a drastic reduction in fund allocation from nearly 18% to just 1%, reflecting uncertainty about sustainable growth in the near term [20]. Conclusion - The pharmaceutical and medical sectors are experiencing a mixed landscape, with certain areas like CXO and innovative drugs showing promise for growth, while IVD faces challenges from policy changes and market dynamics. The overall sentiment remains cautiously optimistic, with potential investment opportunities in recovering sectors.

南方财经全媒体记者 陈思琦 深圳报道 "生命健康领域的技术迭代非常快。衡量初创企业时，我们十分看重团队的原创差异化研发能力、国际 化能力，以及成本控制能力。"高特佳投资副总经理于建林说。 弗若斯特沙利文（Frost & Sullivan）统计显示，2024年中国创新药市场规模超过1.13万亿元，在医疗器 械领域也跃升为仅次于美国的全球第二大市场。 万亿蓝海催生了可观的创业与投资机会。在深圳南山区，不足200平方公里的区域内集聚健康元、康哲 药业、海王生物、康泰生物、微芯生物、未知君等147家生物医药重点企业，以及以迈瑞医疗、开立医 疗为代表的415家医疗器械重点企业，一批初创企业也正在政策与资本的护航下成长。 今年3月，《南山区支持创新创业"六个一"行动方案》印发。其中的"一笔钱"政策提到，设立总规模5亿 元的战略直投专项种子基金和天使基金，同时依托"X-Day"西丽湖路演社，"投贷保"联动，为人工智 能、生物医药等重点产业领域企业提供多渠道、全周期的融资对接服务。 所谓"X-Day"西丽湖路演社，即每月第一个星期四聚焦一个行业，在西丽湖大学城举办专场路演，高效 链接资本与项目。 5月8日，"X-Day"举行 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][3]. Core Views - The company reported a revenue of 469 million yuan in 2024, a decrease of 3.13%, with a net profit of 141 million yuan, down 4.08%. However, the fourth quarter of 2024 showed strong performance with a revenue of 106 million yuan, an increase of 29.77%, and a net profit of 42 million yuan, up 733.85% [1][9]. - The company is focusing on expanding its ultrasound matrix and the application of SonoAI technology to enhance product competitiveness [1][9]. - The gross margin remained stable at 58.95%, while the R&D expense ratio increased to 16.99%, reflecting the company's commitment to building technological barriers through increased R&D investment [2][15]. - The company is deeply engaged in the ultrasound AI field, driving innovation across various clinical disciplines, including breast, liver, cardiovascular, carotid, thyroid, and obstetrics and gynecology [2][20]. Financial Forecasts - The revenue forecasts for 2025, 2026, and 2027 are adjusted to 560 million yuan, 640 million yuan, and 740 million yuan, respectively, with year-on-year growth rates of 19%, 15%, and 14% [3][20]. - The net profit forecasts for the same period are 170 million yuan, 200 million yuan, and 220 million yuan, with year-on-year growth rates of 21%, 15%, and 15% [3][20]. - The current stock price corresponds to a PE ratio of 19, 17, and 15 for 2025, 2026, and 2027, respectively [3][20].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the gastrointestinal endoscopy industry, specifically focusing on the upcoming launch of the X1 endoscope by Olympus, which holds over 70% market share in the global soft endoscope market [1][1]. Core Insights and Arguments - The launch of the X1 endoscope is anticipated to create a new growth cycle in the gastrointestinal endoscopy sector, with hospitals potentially delaying procurement of gastrointestinal endoscopes until the X1 is available [1][1]. - After the X1's launch, hospitals are expected to engage in concentrated purchasing, leading to a noticeable increase in quarterly revenue growth year-on-year within a year of the product's release [1][1]. - The domestic soft endoscope market is expected to face pressure in 2024 due to reduced bidding scale from policy factors and the fact that only the main unit of the X1 has been approved in China, causing some hospitals to postpone their purchases [1][1]. Future Expectations - The X1 endoscope is projected to be launched in China by the end of this year or early next year, which, combined with favorable policy changes and a prolonged destocking period for soft endoscope companies, may lead to a significant release of demand and improvement in company performance [2][2]. - The technological level of domestic soft endoscopes is continuously improving, gaining recognition from high-level domestic hospitals and initial acceptance in overseas markets. This positions domestic manufacturers to benefit from the industry growth driven by the X1 [3][3]. Investment Recommendations - Companies to watch include Aohua Endoscopy and Kaili Medical, which may benefit from the anticipated market changes and growth opportunities [4][4].

股票研究 /[Table_Date] 2025.05.03 2025-05-07 业绩持续复苏，Q1 发货量大幅增长 海泰新光 2024A & 2025Q1 业绩点评 本报告导读： 24 年前三季度下游客户去库影响发货节奏，24Q3 以来发货逐步恢复，25Q1 发货 量同比增长 40%以上，维持增持评级。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 471 | 443 | 556 | 681 | 826 | | (+/-)% | -1.3% | -5.9% | 25.5% | 22.6% | 21.2% | | 净利润（归母） | 146 | 135 | 179 | 223 | 275 | | (+/-)% | -20.2% | -7.1% | 31.9% | 24.8% | 23.5% | | 每股净收益（元） | 1.21 | 1.12 | 1.48 | 1.85 | 2.28 | | 净资产收益率(%) ...

Group 1 - In April, there was a significant increase in the number of fund institutions conducting research on A-share listed companies, with public funds conducting 9,796 research instances, a 129.47% increase from March, and private funds conducting 7,647 instances, a 117.68% increase [1][3] - The electronic and pharmaceutical industries were the most favored sectors for research, with leading companies like Luxshare Precision being researched 368 times and Lanke Technology 179 times [1][4] - The electronic sector is driven by AI technology breakthroughs, increased computing power demand, and continuous iteration of consumer electronics, while the pharmaceutical sector benefits from the advancement of innovative drug development and high-end medical device localization [3][4] Group 2 - Despite the overall market adjustment in April, only four sectors, including beauty care and agriculture, saw an increase, while the electronic and pharmaceutical indices fell by 4.79% and 2.07%, respectively [3] - Public funds focused their research on 20 major industries, with the electronic industry being the most researched at 1,754 instances, followed by pharmaceuticals at 1,400 instances [3][4] - The characteristics of companies that attract significant research attention include strong performance, prominent industry position, and high growth potential, often supported by market and policy [4][5] Group 3 - Top fund institutions showed the highest frequency of research activities, with 29 institutions conducting over 100 research instances in April [8] - Leading public funds such as Bosera Fund and Huaxia Fund showed strong interest in Luxshare Precision, with research instances reaching 241 and 192, respectively [8][9] - The focus on AI and self-sufficiency in the electronic sector is expected to drive investment opportunities, with a strong emphasis on domestic semiconductor independence and the growth of AI-related hardware [10][11]

简历显示：吴兴武先生:中国籍,理学硕士,持有中国证券投资基金业从业证书,曾任摩根士丹利华鑫基金 管理有限公司研究员,广发基金管理有限公司研究发展部、权益投资一部研究员、广发多元新兴股票型 证券投资基金基金经理(自2017年4月25日至2019年4月16日)、广发核心精选混合型证券投资基金基金经 理(自2015年2月17日至2020年2月10日)、广发鑫瑞混合型证券投资基金(LOF)基金经理(自2019年4月16 日至2020年7月29日)、广发再融资主题灵活配置混合型证券投资基金(LOF)基金经理(自2019年4月16日 至2020年7月31日)。现任广发轮动配置混合型证券投资基金基金经理(自2015年2月12日起任职)、广发医 疗保健股票型证券投资基金基金经理(自2018年10月16日起任职)、广发医药健康混合型证券投资基金基 金经理(自2020年10月21日起任职)、广发创新医疗两年持有期混合型证券投资基金基金经理(自2021年3 月19日起任职)。2022年11月4日起任广发竞争优势灵活配置混合型证券投资基金基金经理。曾任广发主 题领先灵活配置混合型证券投资基金基金经理。 来源：金融界 公开资料显示，广 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)118开立医疗271.9496.034.38136.74亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因-98.61-80.961.4012.76亿9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿 11华大智造-63.30-56.174.36337.46亿 股东方面，截至2025年3月31日，开立医疗股东户数14519户，较上次增加736户，户均持股市值35.28万 元，户均持股数量2.76万股。 来源：金融界 5月6日，开立医疗 ...